Friday, December 21, 2018

What Does a Government Shutdown Mean for Medical Cannabis?

If you have seen the news lately, you know that the possibility of a partial government shutdown is looming. Although Congress has passed funding extensions, the President is threatening to veto any Shutdown.jpgappropriations packages that do not contain sufficient funding for border security. Without further action, much government funding will end at 11:59 PM on Friday, December 21, meaning that many non-essential government operations and agencies will be suspended until a budget is passed. This would NOT include operations at the Department of Justice (DOJ) as it is considered essential.

Source: http://www.safeaccessnow.org/government_shutdown_implications

The post What Does a Government Shutdown Mean for Medical Cannabis? was originally published on Giggles N Dimples Blog



source https://gigglesndimples.com/2018/12/21/what-does-a-government-shutdown-mean-for-medical-cannabis/

FDA Weighs In On Legal Status of Commercially Available ‘Hemp-Derived’ CBD Products

Following yesterday’s passage of the 2018 Farm Bill, US Food and Drug Administration Commissioner Scott Gottleib issued a statement with regard to the agency’s oversight of products commercially marketed as ‘hemp-derived’ CBD.

The FDA states: “We’re aware of the growing public interest in cannabis and cannabis-derived products, including cannabidiol (CBD). This increasing public interest in these products makes it even more important with the passage of this law for the FDA to clarify its regulatory authority over these products. In short, we treat products containing cannabis or cannabis-derived compounds as we do any other FDA-regulated products — meaning they’re subject to the same authorities and requirements as FDA-regulated products containing any other substance. This is true regardless of the source of the substance, including whether the substance is derived from a plant that is classified as hemp under the Agriculture Improvement Act.”

The FDA maintains that nothing in the 2018 Farm Act overrides the authority of the agency “to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act.” It further states: “Additionally, it’s unlawful under the FD&C Act to introduce food containing added CBD or THC into interstate commerce, or to market CBD or THC products as, or in, dietary supplements, regardless of whether the substances are hemp-derived. … We’ll take enforcement action needed to protect public health against companies illegally selling cannabis and cannabis-derived products that can put consumers at risk and are being marketed in violation of the FDA’s authorities.”

It concludes: “While products containing cannabis and cannabis-derived compounds remain subject to the FDA’s authorities and requirements, there are pathways available for those who seek to lawfully introduce these products into interstate commerce. The FDA will continue to take steps to make the pathways for the lawful marketing of these products more efficient.”

Provisions of the 2018 Farm Bill amend the federal Controlled Substances Act of 1970 so that hemp plants containing no more than 0.3 percent THC are no longer classified as a schedule I controlled substance under federal law. The Act also broadens the definition of ‘hemp’ (Section 297A) to include “any part of the plant, including …. extracts [or] cannabinoids” that do not possess greater than 0.3 percent THC on a dry weight basis. This language seemingly allows for the future legalization (under federal law) of some CBD-specific products, presuming they are derived from licensed hemp producers who are in compliance with both state and federal regulations, and are marketed in such a way that does not violate the Food, Drug and Cosmetics Act. However, to date, significant disagreement exists among experts as to whether traditional hemp plants are a viable source for cannabinoid extraction.

NORML Political Director Justin Strekal said that greater oversight of the market is in the best interest of consumers:

“Future regulatory efforts at the state and federal level will likely still be required to address emerging consumer issues when it comes to the commercial sale and marketing of hemp-derived products, particularly so-called hemp-derived CBD extracts,”

“Increasingly, many of the producers of these products have navigated in a dubious grey area of the law — manufacturing products of variable and sometimes questionable quality and safety. It is imperative that lawmakers to craft consistent benchmark safety and quality standards to boost consumer confidence and ultimately be able to hold bad actors accountable as this nascent industry transitions into a legal marketplace.”

You can see the NORML factsheet on CBD by clicking here.

On Background:

What is hemp?

Unlike traditional cannabis, which is primarily grown for the purpose of harvesting its flowers, industrial hemp is a fibrous crop grown mainly for its stalk and seeds — which can be utilized in the manufacturing of textiles, paper, animal feed, food-stuffs and numerous other products. Because only trace levels of THC, the primary psychotropic compound in marijuana, is present in hemp, most countries — including Canada and Japan — appropriately define it as an agricultural crop and not as a controlled substance. In fact, according to the Congressional Research Service, “The United States is the only developed nation in which industrial hemp is not an established crop.”

What is CBD?

Cannabidiol is one of a number of naturally occurring cannabinoids in the cannabis plant. It possesses a number of known therapeutic effects, such as anxioltytic and anti-convulsant effects. Like other cannabinoids, it is most prominent in cannabis flowers, and not in the plant’s stalks. As a result, some experts opine, “Traditional hemp is an inefficient source of CBD.” Federal agencies like the US Food and Drug Administration maintain that CBD sourced from traditional cannabis meets the criteria of a schedule I controlled substance.

Are commercially available CBD products safe and effective?

In recent years, marketers have advertised a variety of ‘hemp-derived’ CBD-related products online and in other venues. However, third-party analytical testing of some of these products has consistently found them to be of varying quality and safety. In some instances, products have been found to contain far lower percentages of CBD than advertised. In other instances, products alleging to be THC-free have been found to possess THC as well as other psychotropic adulterants. Further, in almost all instances, commercially available CBD products contain far lower quantities of CBD than are necessary to yield therapeutic effects in clinical trials.

Source: http://blog.norml.org/2018/12/21/fda-weighs-in-on-legal-status-of-commercially-available-hemp-derived-cbd-products/

The following blog post FDA Weighs In On Legal Status of Commercially Available ‘Hemp-Derived’ CBD Products Find more on: Giggles N Dimples Blog



source https://gigglesndimples.com/2018/12/21/fda-weighs-in-on-legal-status-of-commercially-available-hemp-derived-cbd-products/

The Top 12 Canadian Pot Stocks (Updated)

These 12 stocks are where canna-investors should place their bets. Each company is a licensed producer (LP) of cannabis in Canada. This article has been updated.

1. Canopy Growth Corp. (CGC:US New York)

Market cap: $9.120 billion

Stock price: $26.44

Owns Ontario-based LP, Tweed. With its $4 billion investment made in August, Constellations Brands, whose stable of alcohol companies includes Corona and Mondavi, now owns 38% of Canopy.

2. Tilray Inc. (TLRY:US NASDAQ)

Market cap: $6.659 billion

Stock price: $72.27

Owns the British Columbia-based LP. On Dec. 20, Belgium-based Anheiser-Busch InBev partnered with Tilray to spend $100 million researching CBD and THC non-alcoholic drinks. Each company will pitch in $50 million. A-B InBev owns Budweiser, Stella Artois, Labatt’s and literally hundreds of other beer brands. On Dec. 18, Swiss pharmaceutical giant Novartis (they own Sandoz) inked a deal with Tilray to make medical cannabis products available through Novartis’ distribution network in 35 countries. On Sept. 17, it was reported that the DEA will begin to import cannabis from Tilray for research purposes.

3. Aurora Cannabis Inc. (ACB:US New York)

Market cap: $4.798 billion

Stock price: $4.81

Alberta-based LP also owns Ontario-based LP, MedRelief Corp. as well as subsidiaries CannaMed and Hempco Food and Fiber. On Sept. 17, it was reported that Coca-Cola had contacted Aurora about launching a CBD soft drink in Canada.

4. Cronos Group Inc. (CRON:US NASDAQ)

Market cap: $1.989 billion

Stock price: $10.49

Owns Ontario-based LP, Peace Naturals Project Inc. On Dec. 7, Marlboro cigarette maker Altria Group purchased 45% of Toronto-based Cronos Group (NASDAQ: CRON) for $1.8 billion

5. Aphria Inc. (APHA:US New York)

Market cap: $1.241 billion

Stock price: $4.94

Owns the Ontario-based LP. During the first week in December,  short seller Quintessential Capital criticized Aphria, causing a 50% stock drop.

6. Hexo Corp. (HYYDF:OTC US)

Market cap: $666.285 million

Stock price: $3.24

Owns Quebec-based LP, Hydropothecary. In August, Hexo signed an agreement with Molson Coors Canada to develop non-alcohol cannabis-based beverages.

7. CannTrust Holdings Inc. (CNTTF:OTC US)

Market cap: $476.818 million

Stock price: $4.47

Owns Ontario-based LP, CannaTrust.

8. The Green Organic Dutchman Ltd.   (TGODF:OTC US)

Market cap: $477.493 million

Stock price: $1.77

Owns the Ontario-based LP.

9. OrganiGram Holdings Inc. (OGRMF:OTC US)

Market cap: $412.013 million

Stock price: $3.13

Owns New Brunswick-based LP, Organigram.

10. Supreme Cannabis Company Inc. (SPRWF:OTC US)

Market cap: $269,892 million

Stock price: $0.95

Owns Ontario-based LP, 7 Acres.

11. Emerald Health Therapeutics Inc. (EMHTF:OTC US)

Market cap: $230.526 million

Stock price: $1.67

Owns the British Columbia-based LP.

12. Namaste Technologies Inc. (NXTTF:OTC US)

Market cap: $167.599 million

Stock price: $0.56

Owns Ontario-based LP, CannMart; on Sept. 17, Tilray severed ties with Namaste, who’d agreed to purchase cannabis from them, after it was revealed that Namaste held a shareholders’ party featuring scantily clad nurses in Montreal.

More Canadian Coverage

Summary of C-45, the Bill that Legalized Cannabis in Canada

A View form Vancouver: The Canadian Legalization Challenge

Provinces Take Lead in Canada’s Legalization Ramp-Up

Related

What You Need to Know About High Times’ Public Offering

If you enjoyed this Freedom Leaf article, subscribe to the magazine today!

The post The Top 12 Canadian Pot Stocks (Updated) appeared first on Freedom Leaf.

Source: https://www.freedomleaf.com/canadian-pot-stocks/

The following post The Top 12 Canadian Pot Stocks (Updated) Read more on: Giggles N Dimples



source https://gigglesndimples.com/2018/12/21/the-top-12-canadian-pot-stocks-updated/

Thursday, December 20, 2018

Canadian Company Tilray Makes Deals with Novartis and Anheiser-Busch

It’s a clean sweep. Within the last two weeks, Big Tobacco, Big Pharma and Big Alcohol have all made moves into the Canadian cannabis industry:

• On Dec. 7, Marlboro cigarette maker Altria Group purchased 45% of Toronto-based Cronos Group (NASDAQ: CRON) for $1.8 billion.

• On Dec. 18, Swiss pharmaceutical giant Novartis (they own Sandoz) inked a deal with British Columbia-based Tilray Inc. to make medical cannabis products available through Novartis’ distribution network in 35 countries.

• On Dec. 20, Belgium-based Anheiser-Busch InBev partnered with Tilray to spend $100 million researching CBD and THC non-alcoholic drinks. Each company will pitch in $50 million. A-B InBev owns Budweiser, Stella Artois, Labatt’s and literally hundreds of other beer brands.

TILRAY CEO BRENDAN KENNEDY: “It’s too early to know how big cannabinoid-based beverages will be, but we think it’s a massive opportunity and it’s something we’re interested in investing aggressively in.”

Previously, Canopy Growth and Hexo Group made deals with alcohol companies Constellation Brands and Molson Coors, respectively. Constellation – which owns Corona, Mondavi and other brands – invested $4 billion in Canopy.

About the A-B InBev deal, Tilray’s CEO Brendan Kennedy stated: “It’s too early to know how big cannabinoid-based beverages will be, but we think it’s a massive opportunity and it’s something we’re interested in investing aggressively in.”

After its big week, Tilray’s stock, NASDAQ: TLRY, was up 15% to $79.

Related Articles

The Meteoric Rise of Canada’s Legal Cannabis Industry

The Top 12 Canadian Pot Stocks

The View from Vancouver: Inside Canada’s Legalization Challenge

If you enjoyed this Freedom Leaf article, subscribe to the magazine here

The post Canadian Company Tilray Makes Deals with Novartis and Anheiser-Busch appeared first on Freedom Leaf.

Source: https://www.freedomleaf.com/tilray-novartis-anheiser-busch-deals/

Canadian Company Tilray Makes Deals with Novartis and Anheiser-Busch is republished from https://gigglesndimples.com



source https://gigglesndimples.com/2018/12/20/canadian-company-tilray-makes-deals-with-novartis-and-anheiser-busch/

Farm Bill Provisions Lifting Federal Hemp Ban Become Law

Washington, DC: President Donald Trump today signed legislation into law that includes language lifting the United States’ centuries-long prohibition on domestic, commercial hemp production. The provisions were included within The Agriculture Improvement Act of 2018 (aka ‘The Farm Bill’), which takes effect on January 1, 2019.

“The significance of this law change should not be underemphasized,” NORML Deputy Director Paul Armentano said. “This law marks the first change in the federal classification of the cannabis plant since it was initially classified as a schedule I controlled substance by Congress in 1970, and paves the way for the first federally-sanctioned commercial hemp grows since World War II.”

Language included in the 2014 version of the Farm Bill (Sec. 7606) permitted states to license farmers to cultivate hemp as part of a university-sanction pilot program, but did not allow for the commercialization of the crop.

The hemp-specific provisions of the 2018 Act amend the federal Controlled Substances Act of 1970 so that hemp plants containing no more than 0.3 percent THC are no longer classified as a schedule I controlled substance under federal law.

The Act also broadens the definition of ‘hemp’ (Section 297A) to include “any part of the plant, including …. extracts [or] cannabinoids” that do not possess greater than 0.3 percent THC on a dry weight basis. To date, various commercial products – such as some CBD oils – are advertised as being derived from hemp, although some experts in the field dispute the notion that such plants are an efficient source for cannabinoids.

The Act (Section 297B) permits those US states that wish to possess “primary regulatory authority over the production of hemp” to submit a plan to the US Secretary of Agriculture. The agency has 60 days to approve, disapprove, or amend the plan. In instances where a state-proposed plan is not approved, “it shall be unlawful to produce hemp in that state … without a license.” Federal grant opportunities will be available to licensed commercial farmers, as will the ability for farmers to obtain crop insurance. The Act does not federally recognize non-licensed, non-commercial hemp cultivation activities.

Nothing in the new language (Section 297D) shall “affect or modify” the existing regulatory powers of the US Food and Drug Administration or other agencies with regard to the enforcement of the US Food, Drugs, and Cosmetics Act or the Public Health Service Act. The FDA has previously acknowledged that it will “take action when we see the illegal marketing of CBD-containing products with unproven medical claims. We’re especially concerned when these products are marketed for serious or life-threatening diseases, where the illegal promotion of an unproven compound could discourage a patient from seeking other therapies that have proven benefits.”

NORML Political Director Justin Strekal said: “These changes represent a significant and long overdue shift in US policy. Nonetheless, future regulatory efforts will likely still be required to address emerging consumer issues when it comes to the commercial sale and marketing of certain hemp-derived products, particularly so-called hemp-derived CBD extracts. For years, many of the producers of these products have navigated in a grey area of the law — manufacturing products of variable and sometimes questionable quality and safety. Now it is time for lawmakers to craft consistent benchmark safety and quality standards for hemp-derived CBD in order to increase consumer satisfaction and confidence as this nascent industry transitions into a legal marketplace.”

On Background:

What is hemp?

Unlike traditional cannabis, which is primarily grown for the purpose of harvesting its flowers, industrial hemp is a fibrous crop grown mainly for its stalk and seeds — which can be utilized in the manufacturing of textiles, paper, animal feed, food-stuffs and numerous other products. Because only trace levels of THC, the primary psychotropic compound in marijuana, is present in hemp, most countries — including Canada and Japan — appropriately define it as an agricultural crop and not as a controlled substance. In fact, according to the Congressional Research Service, “The United States is the only developed nation in which industrial hemp is not an established crop.”

What is CBD?

Cannabidiol is one of a number of naturally occurring cannabinoids in the cannabis plant. It possesses a number of known therapeutic effects, such as anxioltytic and anti-convulsant effects. Like other cannabinoids, it is most prominent in cannabis flowers, and not in the plant’s stalks. As a result, some experts opine, “Traditional hemp is an inefficient source of CBD.” Federal agencies like the US Food and Drug Administration maintain that CBD sourced from traditional cannabis meets the criteria of a schedule I controlled substance.

Can’t some states already grow hemp?

Yes. Under Sec. 7606 of the 2014 Farm Act, states may license farmers to cultivate hemp as part of a university-sanction pilot program. Over 40 states have enacted legislation permitting such activity.

Source: http://blog.norml.org/2018/12/20/farm-bill-provisions-lifting-federal-hemp-ban-become-law/

Farm Bill Provisions Lifting Federal Hemp Ban Become Law was originally seen on https://gigglesndimples.com/



source https://gigglesndimples.com/2018/12/20/farm-bill-provisions-lifting-federal-hemp-ban-become-law/

Virginia Delegate Files Bill to Allow Medical Cannabis Use at Schools

Del. Chris HurstVirginia State Delegate Chris L. Hurst (D-12) has filed HB 1720 to allow students registered with Virginia’s medical cannabis program to use their medicine at school and school-sponsored activities.

If passed, the bill would prohibit a school board from suspending or expelling from school attendance a student who possesses or uses Virginia’s allowed medical cannabis oils on school property, on a school bus, or at a school-sponsored activity if they are a registered patient and maintain an unexpired written certification.

“We’ve received emails and calls from concerned parents throughout the Commonwealth who are worried their children could be expelled for using their doctor-recommended medical cannabis oil at school,” said Jenn Michelle Pedini, executive director of Virginia NORML. “Delegate Hurst’s bill would provide a much-needed solution for these families.”

The bill does not provide explicit guidance as to how the medicine would be administered on school property.

Take Action: Click here to send a message to your lawmakers in support of this bill.

Track this and all marijuana-related legislation on Virginia NORML’s 2019 legislation monitoring page.

Source: http://blog.norml.org/2018/12/20/virginia-delegate-files-bill-to-allow-medical-cannabis-use-at-schools/

Virginia Delegate Files Bill to Allow Medical Cannabis Use at Schools was initially published on https://gigglesndimples.com



source https://gigglesndimples.com/2018/12/20/virginia-delegate-files-bill-to-allow-medical-cannabis-use-at-schools/

Excerpt from Ed Rosenthal’s ‘Beyond Buds’: The Rosin Revolution

Rosin is a concentrated blend of terpenes and cannabinoids extracted using a method sometimes called “rosin tech” (RT). It’s the simplest, least-expensive way to extract concentrate from raw buds or hash for more effective dabbing.

Instead of a chemical process, rosin tech relies on heat and pressure to squeeze cannabinoids and terpenes from the source material. It’s a very fast process: A batch of rosin can be produced in moments and consumed immediately. Another advantage of rosin production is that it poses minimal risk of physical injury.

Rosin is the simplest, least-expensive way to extract concentrate from raw buds or hash for more effective dabbing.

The physical science of rosin is simple: Applying heat melts the terpenes and cannabinoids into a pliable resin. Then it’s squeezed using a press. Some lipids and waxes melt at the same temperatures. Thus, the finished product is generally not as refined as the results of some other methods. The tradeoff is the speed and ease of extraction.

There’s a wide range of tools and equipment that can be used to make rosin. The choice depends mostly on the quantity being pressed. On the hobby level, you can use household items. Industrial processors use pneumatic or hydraulic presses.

No matter the size of the project, the start-up costs of this method are very low compared to chemical extraction, where just the cost of the safety equipment and laboratory modifications exceeds the cost of even an elaborate, large-scale rosin operation.

Kief can be used to make rosin

Starting Material

There are three basic types of material you can press rosin from: buds, hash and kief. Within those categories there are different types and grades.

Buds

Freshly cured, resin-rich flower (small buds and trim are ideal) results in the best rosin, because it’s rich in terpenes and high in cannabinoids. Conversely, older, drier material results in lower yields that are darker, less flavorful and less potent.

An ounce of buds yields about five grams of rosin.

Kief

Dry-sift kief generally contains a high percentage of plant material. The more plant matter removed from the trichome heads, the higher the yields and the cleaner and smoother the resulting rosin.

Hash

When rosin is pressed from hash, it’s a secondary concentration, a refinement of an already concentrated product. This results in a higher concentration of cannabinoids in the rosin.

Sasquash rosin press

Machine Pressing Rosin

Rosin processing, though not a cold process, occurs below the volatilization point for most of the terpenes and doesn’t reach the temperatures needed for decarboxylation. The rosin is mostly a concentration of THCA and/or CBDA, the acidic precursors to the cannabinoids. The result: the material is great for smoking, but will not be intoxicating if eaten.

Choosing a Press

One option for those new to concentrate production is to choose an entry-level, mid-sized, tabletop model press like those made by Sasquash that offer higher-volume capacity than a hair straightener without the investment and storage concerns of a large press.

If you do choose to purchase a press, a big factor is the amount of pressure it produces. You don’t need to buy a press that produces 25 tons of pressure when all you need is two to five tons to press small quantities of hash or bud. Pressing several ounces of bud or hash at one time requires 10 to 25 metric tons of pressure.

Most commercially available, rosin-specific presses are designed to press hash only. If you’re planning to press flower, choose a machine that is designed to handle it. They require more pressure than hash-pressing models.

Tools for Making Rosin

Pre-Press Molds

In addition to the press, there are a number of other items to consider. Pre-press molds are a crucial component of many smaller rosin presses, so it’s important to pay attention to the specs. Pressure affects yield. To maximize pressure, use the same force in the smallest area possible.

Rosin filter bag

Filter Bags

It’s possible to do a “naked press” on a bud—pressing it without any physical screen or filtration to remove plant material. But if you want to further refine your product and confine your material to a condensed area (without the trichome loss incurred using molds or hand pressing), filter bags are an excellent option and should be used for large quantities. They’re available in several micron sizes like bubble bags used in cold-water extraction.

Parchment Paper or PTFE Sheeting

No matter what approach to RT you choose, parchment paper is absolutely essential. That’s parchment paper—NOT WAX PAPER. Make sure the paper you choose doesn’t have any coating.

Making rosin is a sticky endeavor.

Machine Pressing Flower

Pressing buds yields between 10% and 35% of the original material, roughly corresponding to the cannabinoid content of the starting material. If a strain tests around 20%, expect a yield of about 20% of the material’s weight in rosin under optimal conditions. An ounce of buds yields about five grams of rosin.

Before pressing, make sure the relative humidity of the material is just right: too low and your yield and quality will suffer, too high and your rosin will be difficult to collect or will smell and taste like chlorophyll and may even turn green. Generally speaking, you’ll want to use material with a relative humidity level of 55% to 60% You can measure this using a hygrometer, either a basic analog model like what’s found inside a cigar humidor, or purchasing a digital hygrometer for $10 to $15. If your bud is too dry, use a humidity pack like those sold by Boveda specifically for cannabis.

Always cut and fold parchment paper before pressing. Filling or ripping parchment in the middle of a job is messy, awkward and inefficient.

Lowering temperature usually results in higher quality, but this is not always the case, and lower temperatures will reduce yield, sometimes drastically; it depends on the starting material quality and “personality”—the collective idiosyncrasies and physical quirks that affect how it reacts to pressing. A good way to judge how long to keep the bud under pressure is to watch the color of the oil and how it’s flowing. Once the flow starts to darken and slow down, it’s time to remove pressure.

Some producers choose to start high and work their way down, but we recommend starting at a low temp and working up until you notice a deterioration in quality. Your goal is an even balance between yield and quality. You should be able to roughly dial in your ideal temperature for a given strain within four or five test runs. If you want to refine your temperature to the precise “Goldilocks Zone” for pressing, you might need eight to 10 test runs. But once you have a batch dialed in, you’ll be able to use the setting, or combination of settings, for the rest of that run.

A good way to judge how long to keep the bud under pressure is to watch the color of the oil and how it’s flowing. Once the flow starts to darken and slow down, it’s time to remove pressure.

Most rosin extractors heat the material 150º F to 250º F range. This varies based on the material’s relative humidity, which also affects yield. Always check yields and rosin quality at different temperatures to determine the best setting for a particular batch.

Make sure to be consistent with the amount being pressed. Spread the bud so it forms an even layer. Don’t over-process your buds before pressing. Many processors feel like they get a better press from mostly intact buds versus broken or ground material, but others just break everything down to the same size and make an even layer.

Once stems are removed and flower is weighed to the desired amount, place two small buds in the filter bag first and make sure they’re packed into the corners tightly. This prevents loss of oil to the corners. Once they’re packed, fill the bag with the remaining material evenly with no voids and an even thickness of between a quarter inch to a half inch, leaving a one-inch flap for a fold. There will be two additional corners after the fold; fill these voids to ensure even flow and prevent loss.

Once the trichomes have melted, apply full pressure. You should start to see oil flowing from the platens. Depending on how fast the extraction is happening and the amount being pressed, keep pressure on the material for 35 to 90 seconds. The reason for the time variation is that flow rates vary by variety and freshness. Slow-flow flowers require pressure and heat for a longer time period. Fresh flowers with fast-flowing oil should be pulled off the heat quicker.

Oil oozes onto the parchment paper.

Collecting Rosin

Gathering up rosin after pressing is often more challenging than the press itself. Depending on starting material, its moisture, temperature and timing, a wide range of consistencies can happen. It can be a stable, easy-to-gather material or a sticky sap. Hash rosin is more stable (less sticky and gooey) than flower rosin, which is often difficult to gather.

No matter what consistency you’re working with, it’s probably best to work in as cold a room as possible, ideally with cold work surfaces, to increase or maintain the rosin’s manageability while you collect and package it. Make sure you wear gloves to prevent contamination with skin oils and to avoid getting rosin stuck to your hands.

After pressing out the rosin, leave all the papers in the refrigerator for about five minutes to cool everything down and stabilize the oil. Cold plates or cold blocks can be used to help with collection; an aluminum plate left in the refrigerator or sitting on a block of ice is an ideal cold surface.

Avoid scraping parchment paper; this can result in paper particles being scraped into the final product.

Freshly-made rosin using the Sasquash press

Curing and Storage

After collecting the rosin and rolling it into a ball, there are several ways to cure it. A large ball is a good way to protect most of it from oxidization and to prevent the evaporation of terpenes.

Always store rosin in a sealed container in the refrigerator. This preserves terpenes and prevents oxidization. If you don’t plan to weigh it out, leave it in a large ball inside of a sealed container.

The final rosin product

Low-Temp Dabs

Now that you have your resin, we recommend low-temperature dabbing. While hot dabs are how most dabbers were introduced to dabbing, thankfully this is no longer necessary, now that low-temp dabbing has become the majority practice. The key to effective dabbing is finding the ideal balance between preserving the terpenes while activating the cannabinoids. The problem is that the vitalization point of most terpenes is far below the boiling point of most cannabinoids. Compromises must be made.

Lower temps mean higher terps and less activated cannabinoids; higher temps mean lower terps and higher cannabinoid activation. Low-temp dabs utilize low pressure achieved through restricted airflow via a carb cap. Carb caps restrict and direct airflow, lowering the pressure and by extension the boiling points of both the terpenes and cannabinoids present. This allows for a flavorful, low-temp dab that still contains higher levels of active cannabinoids.

Excerpted from Beyond Buds: Next Generation. © 2018 Ed Rosenthal. Reprinted by permission of Quick American Publishing, Piedmont, CA. Written with Greg Zelman.

Related Articles

Rosin: The Hot Concentrate

Ed Rosenthal’s Trimming Tips

Debunking Indica and Sativa

This article appears in Issue 34. Subscribe to the magazine here.

The post Excerpt from Ed Rosenthal’s ‘Beyond Buds’: The Rosin Revolution appeared first on Freedom Leaf.

Source: https://www.freedomleaf.com/ed-rosenthal-rosin-revolution/

The article Excerpt from Ed Rosenthal’s ‘Beyond Buds’: The Rosin Revolution is courtesy of The Giggles N Dimples Blog



source https://gigglesndimples.com/2018/12/20/excerpt-from-ed-rosenthals-beyond-buds-the-rosin-revolution/